| Literature DB >> 11740815 |
Abstract
Three cases of multiple myeloma treated with thalidomide are presented which highlight therapeutic dilemmas presented by therapy with this new agent. The difficulty of stem cell collection during thalidomide therapy is illustrated. The question of continuation of thalidomide after attainment of a plateau or remission is discussed and the management of neuropathy considered. Thalidomide, being a novel drug, presents a number of therapeutic issues that have yet to be resolved. Copyright 2001 by W.B. Saunders Company.Entities:
Mesh:
Substances:
Year: 2001 PMID: 11740815 DOI: 10.1016/s0093-7754(01)90030-2
Source DB: PubMed Journal: Semin Oncol ISSN: 0093-7754 Impact factor: 4.929